Banqiao District

Researchers are evaluating the effects of two hormone therapy regimens on menopausal symptoms such as overactive bladder, sexual function, depression, autonomic function, arterial stiffness, and atherosclerosis. This study compares tibolone to a combination of estradiol valerate and medroxyprogesterone acetate in women with menopausal syndrome who still have an intact uterus. The goal is to better understand how these treatments impact these symptoms and related health measures. The study involves two treatment groups one receiving tibolone 2.5 mg daily, and the other receiving estradiol valerate 1 mg combined with medroxyprogesterone acetate 2.5 mg daily. This open-label, prospective study enrolls women who have been treated for menopausal syndrome starting from October 2021. Participants will take their assigned hormone therapy daily and be evaluated over 12 weeks. Participants will complete several questionnaires and undergo tests to measure symptoms and health effects at the start, 4 weeks, and 12 weeks after beginning treatment. These include assessments of menopausal symptoms, bladder urgency and severity, sexual function, sleep quality, depression, heart rate variability, arterial stiffness, and atherosclerosis. The research team will compare the results between the two hormone therapy groups to assess their impact on these measures.

Researchers are evaluating the long-term safety of Deucravacitinib compared to Ustekinumab in adults with moderate-to-severe plaque psoriasis. This Phase 3b4 study focuses on cardiovascular events and other health outcomes over an extended period, aiming to understand how these treatments impact patients with psoriasis who have cardiovascular risk factors. The study is led by Bristol-Myers Squibb and involves random assignment of participants to either treatment. Participants receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study is open-label, meaning both participants and researchers know which treatment is being given. This trial runs for up to 5 years, during which patients are monitored for cardiovascular safety and other health events related to their psoriasis treatment. Throughout the study, participants undergo regular assessments to track major cardiovascular events like heart attacks, strokes, and hospitalizations, as well as monitoring for infections, cancer, and treatment side effects. Researchers collect data on liver function and lipid levels up to 60 days after the last dose. The long-term follow-up helps evaluate safety and health outcomes over several years, with study activities continuing until early 2031.

Researchers are investigating how preoperative blood flow in the lining of the uterus endometrium relates to outcomes for patients with endometrial cancer. This observational study focuses on measuring blood flow and endometrial characteristics to understand their connection to patient progression-free survival. The study is sponsored by Far Eastern Memorial Hospital and aims to provide insights into endometrial cancer prognosis using sonography techniques. The study involves using sonography to evaluate the volume, vascularity, and blood flow of the endometrium before surgery. Key measurements include endometrial vascularity indexes VFI, FI, VI, volume, and thickness. These factors will be analyzed in relation to the patients progression-free survival over a 12-month period following diagnosis. Participants will be female patients aged over 20 years diagnosed with endometrial cancer. Researchers will monitor these patients using non-invasive ultrasound scans to assess the endometrial blood flow and volume. The main outcome measured is the correlation between blood flow characteristics and progression-free survival at 12 months. The study does not involve treatment interventions and focuses on observation and data collection over time.

Researchers are investigating the role of POLE mutations in women with high-risk endometrial cancer. This observational study aims to determine how common POLE mutations are in these cases and to understand their impact on survival in real-world patients. The study focuses on women who have experienced high-risk, recurrent endometrial cancer treated at a specialized referral center. Participants will undergo analysis to detect POLE mutations in their cancer tissues. The research will include survival analysis to evaluate the effect of these mutations on overall survival over a five-year period. This approach helps to clarify the significance of POLE mutations in high-risk endometrial cancer management. During the study, researchers will collect medical and genetic data from participants and monitor survival outcomes. The main outcome is the prevalence of POLE mutations over two years, with secondary outcomes addressing survival impact over five years. Participants will be observed and data collected without intervention, with the study concluding by the end of 2026.